An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Dacarbazine versus Dacarbazine Alone as First Line Therapy in Patients with Stage IV Melanoma • Phase Ib: to define the safety, tolerability and maximum tolerated dose (MTD) of E7080 administered in combination with dacarbazine in patients with Stage IV melanoma. • Phase II: to evaluate the ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease Estudio de 24 meses, de grupos paralelos, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de E2609 en pacientes con enfermedad de Alzheimer temprana To determine whether elenbecestat (E2609) is superior to placebo on the change from baseline in the Clinical Dementia Rating - Sum Of Boxes (CDR-SB) at 24 months in subjects with Early Alzheimer’s Dis...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A controlled clinical trial to look at the effects of treatment with rufinamide on the body, thought process development and its safety in children aged 1 to 4 years with poorly controlled Lennox Gastaut Syndrome To compare the effect of 2 drug regimens consisting of either rufinamide or any other approved AED of the investigator’s choice as an add-on to the subject’s existing regimen of 1-3 AEDs on the overal...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations To evaluate the long-term safety and tolerability of E2007 in subjects with Parkinson’s disease (PD) who experience end-of-dose “wearing-off” motor fluctuations

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial seizures The primary objective is to evaluate the safety and tolerability of perampanel (up to12mg/day) given as adjunctive treatment in subjects with refractory partial seizures

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

MORAb003-004 : Essai de phase 3 randomisé évaluant l’efficacité et la tolérance du farletuzumab associé à du carboplatine et du taxane, chez des patientes ayant un cancer de l’ovaire sensible au platine en rechute. [essai clos aux inclusions] L’objectif de cet essai est de comparer l’efficacité de deux doses de farletuzumab associées à une chimiothérapie standard, chez des patientes ayant un cancer de l’ovaire en rechute. Les patientes se...

• Pays France
• Organes Ovaire
• Spécialités Thérapies Ciblées, Chimiothérapie

A Study on the Effect of E5501 (study drug) in Subjects with Chronic Hepatitis C Virus (HCV)-related Thrombocytopenia who are Potential Candidates for Antiviral Treatment To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude BOLD : étude de phase 1-2 évaluant la sécurité, la tolérance et l'efficacité du mésylate d'éribuline associé à de l’irinotecan chez des enfants ayants des tumeurs solides récurrentes ou réfractaires. Les sarcomes représentent environ 6 % de l’ensemble des tumeurs malignes chez l’enfant et l’adolescent. Le type histologique le plus fréquent chez l’enfant est le rhabdomyosarcome qui représente envir...

• Pays France
• Organes Tumeurs solides, Sarcomes
• Spécialités Chimiothérapie, Pédiatrie

A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Disease (GERD) To compare efficacy (i.e. healing and symptom relief) of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg after 4-8 weeks of treatment among subjects with erosive GERD (eG...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Lemborexant for long-term treatment of insomnia disorder in adults Lemborexant para el tratamiento a largo plazo del insomnio en adultos Determine the efficacy of lemborexant 5 mg (LEM5) and 10 mg (LEM10) compared to placebo (PBO) on subjective sleep onset latency (sSOL) after 6 months of treatment in subjects with insomnia disorder ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune